CLEVELAND, Dec. 6 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), announced today that Company is scheduled to present at the Tenth Annual Biotech/Specialty Pharma Industry Conference hosted by the New York Society of Security Analysts (NYSSA) at NYSSA in New York City, on December 12-13.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on December 13, at 2:20 p.m. ET. The presentation will be webcast live and archived on the Company's website

Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is a safe, oral drug used in the past to treat malaria that demonstrates efficacy in vitro, in animal models, and in live tumors removed from patients. Initial test results indicate that CBLC102 can be effective against a number of malignancies, including hormone refractory prostate cancer, renal cell carcinoma (a highly fatal form of kidney cancer), and soft-tissue sarcoma. The Company recently initiated Phase II trials with CBLC102 in hormone refractory prostate cancer at the Cleveland Clinic andCase Western Reserve University Hospital.

The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from apoptosis (programmed cell death). It has shown efficacy as both a protector and mitigator of the effects of Acute Radiation Syndrome (ARS) in rodents and non-human primates and is on an accelerated approval pathway. The Company has recently responded to a Sources Sought Notice from the Department of Defense (DoD) and a Request for Information issued by the Department of Health and Human Services (HHS) for therapeutic treatments to address ARS. Other applications for this technology include protection from cancer treatment side effects.

Cleveland BioLabs management will be available for meetings with investors in New York on December 12-13.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors."

     Rachel Levine
     The Global Consulting Group
     T: (646) 284-9439